H2 Inhalation for Chinese Type 2 Diabetes: Safety & Efficacy StudyScientific Research
original title: Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study
Ziyi Zhao1, Hongxiang Ji2, Yunsheng Zhao3, Zeyu Liu1, Ruitao Sun1, Yuquan Li2 and Tongshang Ni4*
Published: 2023 Year
-
Abstract:
Aim: To analyze the effectiveness and safety of hydrogen inhalation (HI) therapy as an adjunct treatment in Chinese type 2 diabetes mellitus (T2DM) patients in a real-life clinical setting.
Methods: This observational, non-interventional, retrospective, double-arm, 6-month clinical study included T2DM patients receiving conventional anti-diabetes medication with or without HI initiation from 2018 to 2021. Patients were assigned to the HI group or non-HI group (control group) after 1:1 propensity score matching (PSM). The mean change in glycated hemoglobin (HbA1c) after 6 months in different groups was evaluated primarily. The secondary outcome was composed of the mean change of fasting plasma glucose (FPG), weight, lipid profile, and homeostasis model assessment. Logistics regression was performed to evaluate the likelihood of reaching different HbA1c levels after 6-month treatment between the groups. Adverse event (AE) was also evaluated in patients of both groups.
Results: In total, 1088 patients were selected into the analysis. Compared to the control group, subjects in HI group maintained greater improvement in the level of HbA1c (-0.94% vs -0.46%), FPG (-22.7 mg/dL vs -11.7 mg/dL), total cholesterol (-12.9 mg/dL vs -4.4 mg/dL), HOMA-IR (-0.76 vs -0.17) and HOMA-β (8.2% vs 1.98%) with all p< 0.001 post the treatment. Logistics regression revealed that the likelihood of reaching HbA1c< 7%, ≥ 7% to 1% reduction at the follow-up period was higher in the HI group, while patients in the control group were more likely to attain HbA1c ≥ 9%. Patients in HI group was observed a lower incidence of several AEs including hypoglycemia (2.0% vs 6.8%), vomiting (2.6% vs 7.4%), constipation (1.7% vs 4.4%) and giddiness (3.3% vs 6.3%) with significance in comparison to the control group.
Conclusion: HI as an adjunct therapy ameliorates glycemic control, lipid metabolism, insulin resistance and AE incidence of T2DM patients after 6-month treatment, presenting a noteworthy inspiration to existing clinical diabetic treatment.
1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843
2. Ramachandran A, Snehalatha C, Shetty AS, Nanditha AJW. Trends in prevalence of diabetes in Asian countries. World J Diabetes (2012) 3:110. doi: 10.4239/wjd.v3.i6.110
3. Ogurtsova K, Fernandes JDdR, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract (2017) 128:40–50. doi: 10.1016/j.diabres.2017.03.024
4. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care (2018) 41:963–970. doi: 10.2337/dc17-1962
5. Association AD. 6. glycemic targets: standards of medical care in diabetes-2020. Diabetes Care (2020) 43:S66–76.
6. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (Easd). Diabetologia (2018) 61(12):2461–98. doi: 10.1007/s00125-018-4729-5
7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care (2015) 38:140–9. doi: 10.2337/dc14-2441
8. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocrine Practice (2016) 22:84–113. doi: 10.4158/EP151126.CS
9. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2013) 12:153–75. doi: 10.1517/14740338.2013.752813
10. Ahrén B, Foley J, Bosi EJD. Obesity & metabolism. clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obesity & Metabolism (2011) 13:193–203. doi: 10.1111/j.1463-1326.2010.01321
11. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Treatment regimens with insulin analogues and haemoglobin A1c target of< 7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract (2011) 92:1–10. doi: 10.1016/j.diabres.2010.08.006
12. Mody R, Huang Q, Yu M, Zhao R, Patel H, Grabner M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the united states. Diabetes, Obesity & Metabolism (2019) 21:920–9. doi: 10.1111/dom.13603
13. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes care (2017) 40(11):1425–32. doi: 10.2337/dc16-1974
14. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA (2017) 317:2515–23. doi: 10.1001/jama.2017.7596
15. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. a consensus statement from the international diabetes federation. Diabetic Medicine (2006) 23:469–80. doi: 10.1111/j.1464-5491.2006.01858.x
16. Betteridge DJJM. What is oxidative stress? Metabolism (2000) 49(2):3–8. doi: 10.1016/S0026-0495(00)80077-3
17. Hong Y, Chen S, Zhang JM. Hydrogen as a selective antioxidant: a review of clinical and experimental studies. J Int Med Res (2010) 38:1893–903. doi: 10.1177/147323001003800602
18. Bevilacqua E, Gomes SZ, Lorenzon AR, Hoshida MS, Amarante-Paffaro AM. NADPH oxidase as an important source of reactive oxygen species at the mouse maternal–fetal interface: putative biological roles. Reproductive Biomedicine Online (2012) 25:31–43. doi: 10.1016/j.rbmo.2012.03.016
19. Burtenshaw D, Kitching M, Redmond EM, Megson IL, Cahill PAJF. Reactive oxygen species (ROS), intimal thickening, and subclinical atherosclerotic disease. Front Cardiovasc Med (2019) 6:89. doi: 10.3389/fcvm.2019.00089
20. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia (1997) 40:647–53. doi: 10.1007/s001250050729
21. Pearson JF, Pullar JM, Wilson R, Spittlehouse JK, Vissers M, Skidmore PM, et al. Vitamin c status correlates with markers of metabolic and cognitive health in 50-year-olds: findings of the CHALICE cohort study. Nutrients (2017) 9:831. doi: 10.3390/nu9080831
22. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud CJJ. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 297:842–57. doi: 10.1001/jama.297.8.842
23. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al. Effects of long-term vitamin e supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 293:1338–47. doi: 10.1001/jama.293.11.1338
24. Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Med (2007) 13:688–94. doi: 10.1038/nm1577
25. Ge L, Yang M, Yang N-N, Yin X-X, Song W.-G.. Molecular hydrogen: a preventive and therapeutic medical gas for various diseases. Oncotarget (2017) 8:102653. doi: 10.18632/oncotarget.21130
26. Li S, Fujino M, Ichimaru N, Kurokawa R, Hirano S, Mou L, et al. Molecular hydrogen protects against ischemia-reperfusion injury in a mouse fatty liver model via regulating HO-1 and Sirt1 expression. Sci Rep (2018) 8:14019. doi: 10.1038/s41598-018-32411-4
27. Huang J-L, Liu W-W, Sun X-J. Hydrogen inhalation improves mouse neurological outcomes after cerebral ischemia/reperfusion independent of anti-necroptosis. Med Gas Res (2018) 8:1. doi: 10.4103/2045-9912.229596
28. Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N, et al. Pilot study of h-2 therapy in parkinson’s disease: A randomized double-blind placebo-controlled trial. Movement Disord (2013) 28:836–9. doi: 10.1002/mds.25375
29. Li J, Wang C, Zhang JH, Cai J-M, Cao Y-P, Sun X-J. Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced alzheimer’s disease by reduction of oxidative stress. Brain Res (2010) 1328:152–61. doi: 10.1016/j.brainres.2010.02.046
30. Kato R, Nomura A, Sakamoto A, Yasuda Y, Amatani K, Nagai S, et al. Hydrogen gas attenuates embryonic gene expression and prevents left ventricular remodeling induced by intermittent hypoxia in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol (2014) 307:H1626–33. doi: 10.1152/ajpheart.00228.2014
31. Yu Y-S, Zheng H. Chronic hydrogen-rich saline treatment reduces oxidative stress and attenuates left ventricular hypertrophy in spontaneous hypertensive rats. Mol Cell Biochem (2012) 365:233–42. doi: 10.1007/s11010-012-1264-4
32. Song GH, Li M, Sang H, Zhang LY, Li XH, Yao ST, et al. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J Lipid Res (2013) 54:1884–93. doi: 10.1194/jlr.M036640
33. Sada H, Egi H, Ide K, Sawada H, Sumi Y, Hattori M, et al. Peritoneal lavage with hydrogen-rich saline can be an effective and practical procedure for acute peritonitis. Surgery Today (2021) 51:1860–71. doi: 10.1007/s00595-021-02271-z
34. Niu Y, Nie Q, Dong L, Zhang J, Liu SF, Song W, et al. Hydrogen attenuates allergic inflammation by reversing energy metabolic pathway switch. Sci Rep (2020) 10:1962. doi: 10.1038/s41598-020-58999-0
35. Zhu B, Cui H, Xu W. Hydrogen inhibits the proliferation and migration of gastric cancer cells by modulating lncRNA MALAT1/miR-124-3p/EZH2 axis. Cancer Cell Int (2021) 21:70. doi: 10.1186/s12935-020-01743-5
36. Chen J-B, Kong X-F, Mu F, Lu T-Y, Lu Y-Y, Xu K-C. Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer. Med Gas Res (2020) 10:75. doi: 10.4103/2045-9912.285560
37. Ming Y, Ma QH, Han XL, Li HY. Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress. Exp Ther Med (2020) 20:359–66. doi: 10.3892/etm.2020.8708
38. Wang QJ, Zha XJ, Kang ZM, Xu MJ, Huang Q, Zou DJ. Therapeutic effects of hydrogen saturated saline on rat diabetic model and insulin resistant model via reduction of oxidative stress. Chin Med J (2012) 125:1633–7. doi: 10.3760/cma.j.issn.0366-6999.2012.09.020
39. Zhang XL, Liu JM, Jin KK, Xu HF, Wang C, Zhang Z, et al. Subcutaneous injection of hydrogen gas is a novel effective treatment for type 2 diabetes. J Diabetes Invest (2018) 9:83–90. doi: 10.1111/jdi.12674
40. Zheng M, Yu H, Xue Y, Yang T, Tu Q, Xiong K, et al. The protective effect of hydrogen-rich water on rats with type 2 diabetes mellitus. Mol Cell Biochem (2021) 476:3089–97. doi: 10.1007/s11010-021-04145-x
41. Kajiyama S, Hasegawa G, Asano M, Hosoda H, Fukui M, Nakamura N, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res (2008) 28:137–43. doi: 10.1016/j.nutres.2008.01.008
42. LeBaron TW, Singh RB, Fatima G, Kartikey K, Sharma JP, Ostojic SM, et al. The effects of 24-week, high-concentration hydrogen-rich water on body composition, blood lipid profiles and inflammation biomarkers in men and women with metabolic syndrome: A randomized controlled trial. Diabetes Metab Syndrome Obesity-Targets Ther (2020) 13:889–96. doi: 10.2147/dmso.S240122
43. Ohta S. Molecular hydrogen as a novel antioxidant: overview of the advantages of hydrogen for medical applications. Methods Enzymol (2015) 555:289–317. doi: 10.1016/bs.mie.2014.11.038
44. Dingley J, Tooley J, Porter H, Thoresen MJS. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke (2006) 37:501–6. doi: 10.1161/01.STR.0000198867.31134.ac
45. Szabó C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov (2007) 6:917–35. doi: 10.1038/nrd2425
46. Ahlqvist E, Storm P, Karajamaki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol (2018) 6:361–9. doi: 10.1016/s2213-8587(18)30051-2
47. Aronson R, Orzech N, Ye CL, Goldenberg R, Brown V. Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC diabetes registry database. J Diabetes (2016) 8:76–85. doi: 10.1111/1753-0407.12257
48. Cantrell RA, Alatorre CI, Davis EJ, Zarotsky V, Le Nestour E, Carter GC, et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab (2010) 12:845–57. doi: 10.1111/j.1463-1326.2010.01248.x
49. Zaharia OP, Strassburger K, Strom A, Bonhof GJ, Karusheva Y, Antoniou S, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol (2019) 7:684–94. doi: 10.1016/s2213-8587(19)30187-1
50. Liu C, Kurokawa R, Fujino M, Hirano S, Sato B, Li X-K. Estimation of the hydrogen concentration in rat tissue using an airtight tube following the administration of hydrogen via various routes. Sci Rep (2014) 4:1–11. doi: 10.1038/srep05485
51. Xun ZM, Zhao QH, Zhang Y, Ju FD, He J, Yao TT, et al. Effects of long-term hydrogen intervention on the physiological function of rats. Sci Rep (2020) 10:18509. doi: 10.1038/s41598-020-75492-w
52. Amitani H, Asakawa A, Cheng KC, Amitani M, Kaimoto K, Nakano M, et al. Hydrogen improves glycemic control in Type1 diabetic animal model by promoting glucose uptake into skeletal muscle. PloS One (2013) 8:e53913. doi: 10.1371/journal.pone.0053913
53. Aslam M, Aggarwal S, Sharma KK, Galav V, Madhu SV Postprandial hypertriglyceridemia predicts development of insulin resistance glucose intolerance and type 2 diabetes. Plos One (2016) 11(1):e0145730. doi: 10.1371/journal.pone.0145730
54. Qiu J, Liu Y, Yue Y, Qin Y, Li ZJNR. Dietary tartary buckwheat intake attenuates insulin resistance and improves lipid profiles in patients with type 2 diabetes: a randomized controlled trial. Nutrition Res (2016) 36:1392–401. doi: 10.1016/j.nutres.2016.11.007
55. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2012) 32:2813–20. doi: 10.1161/ATVBAHA.112.300133
56. Nakao A, Toyoda Y, Sharma P, Evans M, Guthrie N. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. J Clin Biochem Nutr (2010) 46:140–9. doi: 10.3164/jcbn.09-100
57. Kamimura N, Nishimaki K, Ohsawa I, Ohta SJO. Molecular hydrogen improves obesity and diabetes by inducing hepatic FGF21 and stimulating energy metabolism in db/db mice. Obesity (2011) 19:1396–403. doi: 10.1038/oby.2011.6
58. Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol (2012) 2012:983814. doi: 10.1155/2012/983814
59. Committee ADAPP. 6. glycemic targets: Standards of medical care in diabetes–2022. Diabetes Care (2021) 45:S83–96. doi: 10.2337/dc22-S006
60. Yoritaka A, Kobayashi Y, Hayashi T, Saiki S, Hattori N. Randomized double-blind placebo-controlled trial of hydrogen inhalation for parkinson’s disease: a pilot study. Neurological Sci (2021) 42:4767–70. doi: 10.1007/s10072-021-05489-4
61. LeBaron TW, Laher I, Kura B, Slezak J. Hydrogen gas: from clinical medicine to an emerging ergogenic molecule for sports athletes. Can J Physiol Pharmacol (2019) 97:797–807. doi: 10.1139/cjpp-2019-0067
Keywords: type 2 diabetes, observational study, hydrogen inhalation, glycemic control, real world study
Citation: Zhao Z, Ji H, Zhao Y, Liu Z, Sun R, Li Y and Ni T (2023) Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study. Front. Endocrinol. 13:1114221. doi: 10.3389/fendo.2022.1114221
